Spero Therapeutics (SPRO) Fundamental Analysis: Revenue, Earnings & Valuation

6.37 / 10

Outperform

Fundamental rating is Outperform with a 6.4/10 quality score. Strengths include high inventory turnover, strong interest coverage, and favorable Asset‑MV and Revenue‑MV metrics. Revenue growth rates are high but flagged as cautionary. Overall fundamentals are encouraging.

Analysis Checks(7/10)

Revenue-MV

Value-1.36

Score3/3

Weight30.48%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value39.24

Score1/3

Weight-1.19%

1M Return-0.38%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.48%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value89.59

Score2/3

Weight1.18%

1M Return0.36%

PB-ROE

Value0.87

Score1/3

Weight24.63%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.02

Score3/3

Weight2.67%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.53%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value39.24

Score1/3

Weight-0.94%

1M Return-0.30%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.34%

1M Return-1.13%

Asset-MV

Value-0.49

Score3/3

Weight53.52%

1M Return11.61%

Is SPRO fundamentally strong?

SPRO scores 6.37/10 on fundamentals and holds a Discounted valuation at present. Backed by its 16.31% ROE, 12.83% net margin, 15.38 P/E ratio, 2.23 P/B ratio, and 111.81% earnings growth, these metrics solidify its Outperform investment rating.